Oruka Therapeutics
ORKA
12 hedge funds and large institutions have $1.96M invested in Oruka Therapeutics in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 6 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
127% more capital invested
Capital invested by funds: $863K → $1.96M (+$1.09M)
1.55% more ownership
Funds ownership: 0.06% → 1.61% (+1.6%)
20% less funds holding
Funds holding: 15 → 12 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Aveo Capital Partners
Englewood,
Colorado
|
+$677K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$268K |
| 3 |
Renaissance Technologies
New York
|
+$227K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$38.5K |
| 5 |
QT
Quantamental Technologies
White Plains,
New York
|
+$38.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$67.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$31K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$27K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$19K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$18K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACP
1
Aveo Capital Partners
Englewood,
Colorado
| $661K | +$677K | +7,544 | +1,746% |
|
|
2
Renaissance Technologies
New York
| $589K | +$227K | +2,533 | +61% |
|
|
TCM
3
Tekla Capital Management
Boston,
Massachusetts
| $264K | -$67.3K | -750 | -20% |
|
|
4
Hudson Bay Capital Management
Stamford,
Connecticut
| $263K | +$268K | +2,989 | New |
|
|
5
Acadian Asset Management
Boston,
Massachusetts
| $128K | +$38.5K | +429 | +42% |
|
|
QT
6
Quantamental Technologies
White Plains,
New York
| $38K | +$38.5K | +429 | New |
|
7
UBS Group
Zurich,
Switzerland
| $13K | +$13.6K | +151 | New |
|
8
Morgan Stanley
New York
| $1K | – | – | – |
|
|
9
Citadel Advisors
Miami,
Florida
| – | -$31K | -379 | Closed |
|
|
10
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$27K | -337 | Closed |
|
|
11
Vanguard Group
Malvern,
Pennsylvania
| – | -$19K | -234 | Closed |
|
|
12
Geode Capital Management
Boston,
Massachusetts
| – | -$18K | -225 | Closed |
|
13
Northern Trust
Chicago,
Illinois
| – | -$5K | -65 | Closed |
|
|
TSS
14
Two Sigma Securities
New York
| – | -$5K | -58 | Closed |
|
ORKA Hedge Fund Activity: Q2 2019 in Review
12 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q2 2019, worth a combined $1.96M — up 127% from $863K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ORKA and 3 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 3 added.
The largest buyer was Aveo Capital Partners, adding an estimated $677K. The largest seller was Tekla Capital Management, cutting an estimated $67.3K.
- 12 institutional investors held Oruka Therapeutics (ORKA) as of Q2 2019, down from 15 in Q1 2019.
- Funds reported $1.96M of Oruka Therapeutics stock for Q2 2019, up 127% quarter-over-quarter.
- 3 funds opened new Oruka Therapeutics positions in Q2 2019 and 6 closed out, a net change of -3 holders.
- The largest Oruka Therapeutics buyer in Q2 2019 was Aveo Capital Partners, an estimated $677K added.
- The largest Oruka Therapeutics seller in Q2 2019 was Tekla Capital Management, an estimated $67.3K sold.
Based on aggregated 13F filings for Q2 2019.